Clinical trials: Contrast Induced Nephropathy
Renal Insufficiency
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial.
- Trial name
- RESCUE (NCT00650845)
- Testing
- Dotarem®-enhanced MRI, non-enhanced MRI
- Where
- 15 sites in Belgium, France and 2 more
- Volunteers
- 135 people
- Sponsor
- Guerbet
Nephropathy
Efficacy of Statins In Prevention of CIN
To determine if statin therapy plus intravenous normal saline, in patients with chronic renal insufficiency undergoing angiography, is superior to placebo plus intravenous normal saline therapy in the prevention of CIN.
- Trial name
- SCIN (NCT01071993)
- Testing
- atorvastatin
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Aortic Aneurysm, Contrast Induced Nephropathy
Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study
The purpose of the study is to determine if the dose of contrast (Omnipaque) administered for Computed Tomography Arteriograms (CTA) can be reduced without degradation of image quality.
- Conditions
- Aortic Aneurysm, Contrast Induced Nephropathy, Aortic and Arterial Anomalies
- Trial name
- NCT02669784
- Testing
- Low Dose Contrast (Omnipaque) 40mL, Low Dose Contrast (Omnipaque) 50 mL
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Milton S. Hershey Medical Center
Emergent Coronary Procedure
Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection
This study is to investigate the effect of Sodium Bicarbonate bolus injection in patients undergoing an emergent coronary procedure for prevention of contrast-induced nephropathy.
- Trial name
- NCT00700375
- Testing
- Sodium bicarbonate, Sodium Chloride
- Where
- Japan
- Volunteers
- 59 people
- Sponsor
- Osaka General Medical Center
Contrast Induced Nephropathy (CIN)
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
- Trial name
- AVERT™ (NCT01976299)
- Testing
- AVERT
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 578 people
- Sponsor
- Osprey Medical, Inc
Radiocontrast-induced Nephropathy
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Millions of people receive radiographic contrast material for investigations like CT and coronary angiography. While considered safe in healthy patients, it can cause acute renal impairment.
- Trial name
- NCT00558142
- Testing
- Acetylcysteine, Visipaque 320
- Where
- United Kingdom
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Contrast-induced Acute Kidney Injury
Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury
This a prospective, double-blind, sham-controlled, randomized clinical trial to study the effects of remote ischemic preconditioning on acute kidney injury, vascular and renal biomarkers in patients with non-ST elevation…
- Trial name
- BRICK (NCT03236441)
- Testing
- RIPC
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Oladipupo Olafiranye, MD, MS
Acute Kidney Injury
Double-Blind Placebo-Controlled CIN Trial
This double-blinded placebo-controlled study will examine the incidence and significance of contrast-induced acute kidney injury following IV iodine-based contrast material administration in subjects with stage IIIB or stage IV…
- Trial name
- NCT02467075
- Testing
- Iopamidol 300 (Contrast)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan
Contrast Induced Nephropathy
Contrast Nephropathy and Nitrates
Contrast-induced nephropathy (CIN) is a complication of percutaneous coronary angiography that occurs in about 10 to 20% of patients exposed to contrast media.
- Trial name
- CoNaN (NCT01999517)
- Testing
- Intravenous Nitroglycerin, IV Fluids
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Acute Kidney Injury, Pulmonary Embolism
Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT
Both, CT scans and VQ scans, are used by doctors to look for pulmonary embolism. The most common reason to order a VQ scan is to avoid the IV dye.
- Conditions
- Acute Kidney Injury, Pulmonary Embolism, Contrast-induced Nephropathy
- Trial name
- VQ/CT (NCT03116139)
- Testing
- V/Q imaging, Computed tomography scan
- Where
- 5 sites in United States
- Volunteers
- 253 people
- Sponsor
- Indiana University
Renal Failure
Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy
The purpose of this study is to determine whether hydration with sodium bicarbonate is superior to hydration with saline to prevent contrast-induced nephropathy.
- Trial name
- NCT01172353
- Testing
- sodium bicarbonate, saline
- Where
- Brazil
- Volunteers
- 301 people
- Sponsor
- Hospital Sao Lucas da PUCRS
Chronic Renal Insufficiency, Diabete Mellitus
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus…
- Conditions
- Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
- Trial name
- NCT01252810
- Testing
- GE-145
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- GE Healthcare
Fibrosis, Kidney Failure
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled…
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Trial name
- NCT00744939
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- Bayer
Nephropathy
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
The purpose of this study is to compare the efficacy of oral N-acetylcysteine and intravenous sodium bicarbonate for the prevention of Contrast-Induced Nephropathy (CIN) after cardiac catheterization.
- Trial name
- PROTECt (NCT00579995)
- Testing
- Oral N-Acetylcysteine, Sodium Bicarbonate
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Renal Impairment
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography.
- Trial name
- CINOPSIS CT (NCT00793182)
- Testing
- Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
- Where
- 13 sites in United States
- Volunteers
- 6 people
- Sponsor
- Guerbet
Chronic Kidney Disease
RenalGuard System and Contrast Media
The purpose of the present study is to assess the role of the RenalGuard System as compared to the optimal strategy (sodium bicarbonate infusion plus N-acetylcysteine (NAC)) in high and very-high risk patients to prevent…
- Trial name
- REMEDIALII (NCT01098032)
- Testing
- RenalGuard system, Systemic alone therapy
- Where
- 4 sites in Italy
- Volunteers
- 294 people
- Sponsor
- Clinica Mediterranea